Basel, March 16, 2026
Roche announced the launch of a large-scale NVIDIA-powered AI factory, marking a major advancement in AI-driven drug discovery, diagnostics development, and pharmaceutical innovation. The new infrastructure integrates 2,176 NVIDIA Blackwell GPUs, bringing Roche’s total computing capacity to over 3,500 GPUs, making it the largest hybrid-cloud AI factory in the pharmaceutical industry.
AI Infrastructure Transforming Drug Discovery and Development
Roche’s new AI factory represents a high-performance supercomputing platform designed to accelerate the entire pharmaceutical value chain, from early-stage discovery to clinical development and commercialization. By leveraging advanced AI models and high-quality biomedical data, the company aims to significantly reduce drug development timelines and improve research efficiency. The integration of NVIDIA BioNeMo technology enhances Roche’s “Lab-in-the-Loop” approach, enabling scientists to connect biological experiments with AI-driven models, allowing for rapid hypothesis testing and large-scale data analysis. This capability enables researchers to explore complex biological systems and molecular interactions at an unprecedented scale, ultimately improving the speed and accuracy of therapeutic discovery.
Enhancing Clinical Trials, Manufacturing, and Diagnostics
Beyond drug discovery, the AI factory is designed to deliver end-to-end transformation across clinical trials, manufacturing, and diagnostics. The platform supports more efficient clinical trial design and execution, enabling faster patient recruitment, optimized study protocols, and improved data interpretation. In manufacturing, Roche is deploying AI-powered digital twins, virtual replicas of production systems that allow engineers to simulate, optimize, and scale manufacturing processes, improving operational efficiency and product quality. In diagnostics, advanced computing tools such as NVIDIA Parabricks enable rapid analysis of large genomic datasets, while AI-driven digital pathology solutions can detect subtle disease patterns across thousands of medical images, enhancing diagnostic precision. These capabilities collectively contribute to faster, more reliable healthcare solutions and improved patient outcomes.
Advertisement
Driving Digital Transformation in Healthcare
The AI factory is a cornerstone of Roche’s broader vision to build an AI-accelerated healthcare organization, where artificial intelligence is embedded across all operations to complement human expertise. By expanding access to supercomputing and AI capabilities, Roche empowers its global workforce to tackle complex disease challenges, including oncology, neurology, and rare diseases. The collaboration with NVIDIA, initiated in 2023, continues to strengthen Roche’s leadership in AI-driven pharmaceutical innovation, enabling the company to shorten the path from biological insight to life-saving medicine. This transformation reflects a broader industry shift toward data-driven, AI-enabled healthcare ecosystems, where advanced computing plays a critical role in improving drug discovery, diagnostics, and patient care.
Source: Roche press release
